论文部分内容阅读
目的:对乳腺癌患者术后服用三苯氧胺(TAM)导致子宫内膜病变患者的病理变化情况进行研究。方法:将本院2012年3月-2015年3月收治的经B超检查或者服用TAM出现阴道不规则出血的55例乳腺癌患者作为研究对象,分成绝经前组17例和绝经后组38例,对两组患者均行宫腔镜检查和子宫内膜活检。结果:两组不规则阴道出血发生率、B超内膜厚度、宫腔深度比较,差异无统计学意义(P>0.05);绝经前组宫腔内异常回声率明显低于绝经后组(P>0.05),绝经后组发生率与绝经前组比较,差异具有统计学意义(P<0.05);子宫内膜癌发病率受到服药时间、子宫内膜厚度等因素影响。结论:乳腺癌患者术后服用TAM治疗,会提高子宫内膜病变风险,主要受到服药时间与子宫内膜厚度等方面因素影响。
Objective: To study the pathological changes of patients with endometrial lesions after tamoxifen (TAM) treatment. Methods: Fifty-five patients with breast cancer who underwent B-mode ultrasound or irregular vaginal bleeding from TAM admitted from March 2012 to March 2015 in our hospital were divided into premenopausal group (n = 17) and postmenopausal group (n = 38) Hysteroscopy and endometrial biopsy were performed on both groups. Results: There was no significant difference in the incidence of irregular vaginal bleeding between the two groups (P> 0.05). The abnormal uterine cavity echo rate in premenopausal group was significantly lower than that in postmenopausal group (P > 0.05). The incidence of postmenopausal group was significantly higher than that of premenopausal group (P <0.05). The incidence of endometrial cancer was influenced by the time of taking medicine and the thickness of endometrium. Conclusion: The postoperative TAM treatment of breast cancer patients will increase the risk of endometrial lesions, which is mainly affected by factors such as medication duration and endometrial thickness.